Kaplan–Meier survival analysis indicated that the patients with high TGFβ2 expression had significantly shorter survival (median survival = 13.0 months) than the patients with lower tumor TGFβ2 expression (median survival = 25.0 months) (log‐rank = 5.65, P < 0.05, Figure 1F, Table S1, Supporting Information). The gene discussed is TGFB2; the disease is neoplasm.